E. Maartense

Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study

Gϋnter von Minckwitz, Andreas du Bois, Marcus Schmidt et al. · Journal of Clinical Oncology · 2009 · 687 citations

Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to <i>BRAF</i> Mutation and Mismatch Repair Status of the MOSAIC Study

Thierry André, Armand de Gramont, Déwi Vernerey et al. · Journal of Clinical Oncology · 2015 · 658 citations

Clinical Relevance of BCL2, BCL6, and MYC Rearrangements in Diffuse Large B-Cell Lymphoma

M Krámer, Jos Hermans, E.R. Wijburg et al. · Blood · 1998 · 488 citations

Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)

Erik J. Blok, Judith R. Kroep, Elma Meershoek‐Klein Kranenbarg et al. · JNCI Journal of the National Cancer Institute · 2017 · 196 citations · Full text

Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer

Gϋnter von Minckwitz, Kathrin Schwedler, Marcus Schmidt et al. · European Journal of Cancer · 2011 · 183 citations

Breast Oncology, Medicine, Pathology +7